Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11717

    +

    P2.10-025 - Weekly paclitaxel (wPCT) for pre-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): a single institution experience in the daily clinical practice. (ID 1527)

    09:30 - 09:30  |  Author(s): A. Caldara
    • Abstract

    Background
    Pemetrexed and docetaxel represent the reference treatments as second line chemotherapy for pts with aNSCLC after failure of a platinum-based treatment, with a response rate (RR) < 10%. However, non-squamous aNSCLC pts could have received pemetrexed into the first line setting and docetaxel may present a relevant side effects burden, in both 3-week and weekly schedules. wPCT is a well tolerated drug which proved to be active in aNSCLC. In the attempt to improve pts compliance we adopted wPCT in the daily practice.

    Methods
    From January, 2010, all pts with aNSCLC progressing after platinum-based chemotherapy and eligible for further chemotherapy received wPCT at 80 mg/sqm for 6 consecutive weeks, followed by a 2-week rest. In absence of clinical evidence of progressive disease at least two courses of wPCT were planned before instrumental re-staging. Responders pts continued the treatment up to a maximum of 4 courses.

    Results
    From January, 2010 to October 2012 a consecutive series of 43 pts was treated with wPCT. The median age was 62 yrs (range 32-74); all but two presented metastatic disease at the diagnosis. Thirty-three, 5, and 5 pts received wPCT as second, third and fourth line treatment, respectively. Five pts received only 1 wPCT course, 30 pts 2 courses, 3 pts 3 courses, and 5 pts 4 courses, for a total number of 94 administered courses. wPCT was well tolerated: only 2 pts experienced a grade 3 toxicity (1 pt liver and 1 pt diarrhea). No toxicity-related treatment interruptions were recorded. Nine pts (21%) achieved a partial response and 9 a stable disease. After a median follow-up of 9 mos, the median PFS and OS were 4 and 11 mos, respectively. The 1-y OS was 30.2%.

    Conclusion
    From our experience wPCT in daily clinical practice may represent a reasonable chemotherapeutic option for pre-treated aNSCLC pts, with a manageable toxicity profile, and may provide disease control rates comparable to those of docetaxel and pemetrexed.